A metabolic shift toward FAO, associated with the upregulation of antioxidant gene programs, has been reported in cycling cells emerging in EGFR mutant PC9 NSCLC cell cultures during treatment with osimertinib [67]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.